Professor Prithviraj Bose joins us at the EHA annual meeting in Amsterdam to discuss his presentation on sotatercept (ACE-011) in subjects with MPN-associated myelofibrosis and anaemia.
Questions
1. What are the limitations of ruxolitinib treatment for MPN-associated myelofibrosis? (0:05)
2. What is the mechanism of action of sotatercept? (0:55)
3. What is the rationale for combining sotatercept with ruxolitinib? (1:36)
4. Could you tell us a little about your recent phase II study of sotatercept and its findings? (2:27)
5. Which other emerging therapies for MPN-associated myelofibrosis seem promising? (3:48)
Filmed at the European Hematology Association (EHA) 24th congress 2019, Amsterdam, Netherlands.
touchONCOLOGY.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
